Searchable abstracts of presentations at key conferences in endocrinology

ea0063p1052 | Pituitary and Neuroendocrinology 3 | ECE2019

Long-term treatment of chronic refractory SIADH with tolvaptan in the elderly: A report of three cases

Stutz Beryl , Henzen Christoph , Fischli Stefan

Background: Hyponatremia due to the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a very common electrolyte disorder in older patients leading often to hospital admissions. Symptoms can vary between mild disabilities (e.g. nausea, dizziness, attention deficits, gait disturbance) to severe life-threatening conditions (e.g. seizures, coma). Treatment of SIADH is challenging in particular when fluid restriction is limited or even not effective in restoring n...

ea0037ep1279 | Clinical Cases–Thyroid/Other | ECE2015

Similia similibus curentur: a novel treatment approach in endocrinology?

Streuli Regina , Slahor Lea , Burget Lukas , Henzen Christoph , Fischli Stefan

Introduction: Hyperinsulinaemic hypoglycemia after gastric bypass surgery is a rare but probably underestimated complication. The mechanisms leading to hypoglycemia are complex and incompletely understood and involve several factors: A part from decreasing insulin resistance, caloric restriction and alteration of nutrient delivery, enhanced secretion of insulin and incretins (GLP1 and GIP), altered physiology of other hormones and dysregulation of counterregulatory effectors s...

ea0070ep396 | Reproductive and Developmental Endocrinology | ECE2020

Unusual manifestation of an endocrine-active testicular tumor

Steighardt Anna , Axel Rüfer , Dominik Högger , Christoph Henzen , Stefan Fischli

Introduction: Leydig cell tumors (LCT) are rare testicular tumors, characterized by mostly benign etiology. Due to their secretory activity androgen- and/or estrogen-excess can occur.Case report: A 42-year old patient with recent history of cerebrovascular incident was admitted to the hematology department for diagnostic work-up of new-onset erythrocytosis (hemoglobin 185 g/l [reference 127–163], hematocrit 0.53 [0.37–0.46]). Myeloproliferati...

ea0020p568 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Long-term follow-up of female patients with prolactinoma: is there a place for surgery in the therapy of prolactinoma?

Frey Janine , Krull Ina , Sahli Rahel , Stettler Christoph , Fischli Stefan , Diem Peter , Christ Emanuel

Background: Medical therapy with dopamine agonists (DA) is the primary treatment in most patients with prolactinomas. ‘Classical’ surgical indications are mainly intolerance of DA therapy or non-responders. Focusing on a possible shift of recent indications towards a surgical approach, we retrospectively analyzed the long-term results of surgical treatment and compared them to the medically treated female patients with prolactinomas.Patients an...

ea0020p569 | Neuroendocrinology, Pituitary and Behaviour | ECE2009

Clinical presentation, long-term follow-up and bone morbidity of male patients with prolactinoma

Frey Janine , Krull Ina , Sahli Rahel , Stettler Christoph , Fischli Stefan , Diem Peter , Christ Emanuel

Background: In contrast to females with prolactinoma, male patients usually present with a history of long-standing hypogonadism and a macroadenoma on MRI-scan. Data is scarce about the effect of hypogonadism on bone health in these patients. We, therefore, investigated retrospectively the cohort of male patients with prolactinoma at our institution.Patients and methods: Between 1983 and 2007, the chards of 44 male patients with prolactinoma were reviewe...

ea0014p104 | (1) | ECE2007

Bone density in patients with non-functioning pituitary adenomas (NFA)

Fischli Stefan , Stettler Christoph , Sahli Rahel , Schwab Silvia , Chappuis Bernard , Jenni Stefan , Diem Peter , Christ Emanuel

Background: Surgically treated patients with NFA often present with secondary hypogonadism. Hypogonadism is a well known risk factor for osteopenia or osteoporosis. The aim of this study was to assess (a) the frequency of osteopenia/osteoporosis in a single centre Swiss cohort of patients with operated NFA and (b) whether gender or hypogonadism impacts on bone density at follow up.Methods: Data of patients with NFAs diagnosed between 1967 and 2005 were a...

ea0037gp.28.02 | Endocrine tumours and neoplasia – NETS | ECE2015

Localisation of insulinoma: comparison of glucagon-like peptide 1 receptor SPECT/CT, PET/CT, and MRI: preliminary results of a prospective clinical study

Antwi Kwadwo , Fani Melpomeni , Heye Tobias , Nicolas Guillaume , Merkle Elmar , Reubi Jean Claude , Gloor Beat , Fischli Stefan , Wild Damian , Christ Emanuel

Purpose: We aim at prospectively comparing the detection rate of glucagon-like peptide 1 receptor (GLP1R) PET/CT vs GLP1R SPECT/CT vs standardised contrast enhanced 3T MRI in patients with endogenous hyperinsulinaemic hypoglycaemia.Methods: 14 patients with neuroglycopenic symptoms due to endogenous hyperinsulinaemic hypoglycaemia were already enrolled (mean age 56 years, ten females and four males). A standardized contrast enhanced 3T MRI was performed....

ea0081oc1.3 | Oral Communications 1: Diabetes, Obesity, Metabolism and Nutrition 1 | ECE2022

Canakinumabin patients with COVID-19 and type 2 diabetes (CanCovDia) – a multicentric, randomised, double-blind, placebo-controlled phase 3 trial

Hepprich Matthias , Mudry Jonathan , Gregoriano Claudia , Jornayvaz Francois R , Carballo Sebastian , Wojtusciszyn Anne , Bart Pierre-Alexandre , Chiche Jean-Daniel , Fischli Stefan , Baumgartner Thomas , Cavelti-Weder Claudia , Beuschlein Felix , Braun Dominque L , Gunthard Huldrych F , West Emily , Conen Anna , Isenring Egon , Bucklar Gabriela , Aubry Yoann , Dey Ludovic , Muller Beat , Schutz Philipp , Cattaneo Marco , Hunziker Patrick , Donath Marc Y

Background: Patients with type 2 diabetes and overweight have a chronic activation of the innate immune system possibly explaining the increased risk of a hyperinflammatory response and severe COVID-19. We aimed to test whether blockade of interleukin-1β(IL-1β) using canakinumab improves clinical outcome.Methods: CanCovDia was a multicenter, randomised, double-blind, placebo-controlled trial to assess the efficacy of canakinumab plus standard-o...